|Videos|September 30, 2016

Prognosis of Babies with Zika-related Complications

Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the prognosis of babies with Zika-related complications.

Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the prognosis of babies with Zika-related complications.

Interview Transcript (slightly modified for readability)

“In the babies that [are] born with microcephaly, other central nervous system malformations, and other extreme malformations, perhaps these babies will need life[-long] complete support, [with regards to] neurology, psychology, physical therapy, and other [complications], because [Zika] is most intense and severe when [babies are] born with this malformation.

Many of [these babies] die in a few minutes, few days, or few weeks after they’re born [with these Zika-related complications]. But those ones that survive will need assistance for [a] lifetime. Of course these babies [have other] immune system problems [because of] Zika virus infection. So they need assistance to fight against [some otherwise harmless] infections properly, [such as] pneumonia, severe diarrhea and other complications that can appear during Zika virus infection in [a] baby that is already born with microcephaly [or] other malformation. Probably the immune system is typically altered.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.